Did You Know?

Editor’s Picks

Latest News

Arcutis Announces Exercise of Option for Exclusive License to Highly Selective JAK1 Inhibitor for All Topical Dermatological Uses in U.S., Canada, Europe and Japan

ARQ-252 potential to offer "Best in Class" topical JAK therapy Phase 2b study in adult patients with hand eczema anticipated...

MorphoSys AG: Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab

error: Content is protected !!